The objective of this study was to compare Ki-67, Bcl-2, Bax, Bak, ER, and PgR expression in postmenopausal women with ER-positive invasive breast cancer (IBC) before and after short-term hormone therapy (HT) with either tamoxifen or anastrozole in order to identify a possible biomarker profile associated with hormone resistance.Fifty-eight patients with palpable IBC were assigned to receive neoadjuvant therapy with either anastrozole, placebo, or tamoxifen for 26 days prior to surgery. Tissue microarray blocks were constructed from pre- and post-treatment biopsy samples and used for immunohistochemical analysis. Biomarker (Ki-67, Bcl-2, Bax, Bak, ER, and PgR) levels were assessed semiquantitatively using the Allred score. A statistical ana...
Purpose: The impact of neoadjuvant chemotherapy (NACT) on immunohistochemical markers in breast canc...
BackgroundAromatase inhibitors such as anastrozole and letrozole are highly effective suppressants o...
Introduction: Fulvestrant shows dose-dependent biological activity. Greater estrogen-receptor (ER) ...
Background: Fulvestrant (FaslodexTM) is an estrogen receptor (ER) antagonist with a distinct mode of...
In this study we demonstrate the change in estrogen receptor (ER) level and cell proliferation in hu...
PURPOSE:To investigate whether estrogen receptor (ER), progesterone receptor (PR) and Ki-67 expressi...
BACKGROUND: The objective of this study was to determine the optimal scheduling of 2.5 mg daily let...
BACKGROUND: The objective of this study was to determine the optimal scheduling of 2.5 mg daily letr...
Purpose Neoadjuvant (preoperative) therapy for breast cancer may allow for the development of interm...
Background Preclinical data suggest that epidermal growth factor receptor (EGFR) inhibitors (e.g. ge...
The study of changes in proliferation as a marker of treatment benefit during presurgical endocrine ...
Purpose: To determine the relationship between quantitative estrogen-receptor (ER) and progesterone-...
Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal ho...
Window studies are gaining traction to assess (molecular) changes in short timeframes. Decreased tum...
International audienceBACKGROUND:The aim of this study was to assess the efficacy of neoadjuvant ana...
Purpose: The impact of neoadjuvant chemotherapy (NACT) on immunohistochemical markers in breast canc...
BackgroundAromatase inhibitors such as anastrozole and letrozole are highly effective suppressants o...
Introduction: Fulvestrant shows dose-dependent biological activity. Greater estrogen-receptor (ER) ...
Background: Fulvestrant (FaslodexTM) is an estrogen receptor (ER) antagonist with a distinct mode of...
In this study we demonstrate the change in estrogen receptor (ER) level and cell proliferation in hu...
PURPOSE:To investigate whether estrogen receptor (ER), progesterone receptor (PR) and Ki-67 expressi...
BACKGROUND: The objective of this study was to determine the optimal scheduling of 2.5 mg daily let...
BACKGROUND: The objective of this study was to determine the optimal scheduling of 2.5 mg daily letr...
Purpose Neoadjuvant (preoperative) therapy for breast cancer may allow for the development of interm...
Background Preclinical data suggest that epidermal growth factor receptor (EGFR) inhibitors (e.g. ge...
The study of changes in proliferation as a marker of treatment benefit during presurgical endocrine ...
Purpose: To determine the relationship between quantitative estrogen-receptor (ER) and progesterone-...
Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal ho...
Window studies are gaining traction to assess (molecular) changes in short timeframes. Decreased tum...
International audienceBACKGROUND:The aim of this study was to assess the efficacy of neoadjuvant ana...
Purpose: The impact of neoadjuvant chemotherapy (NACT) on immunohistochemical markers in breast canc...
BackgroundAromatase inhibitors such as anastrozole and letrozole are highly effective suppressants o...
Introduction: Fulvestrant shows dose-dependent biological activity. Greater estrogen-receptor (ER) ...